Missing Data in the Regulation of Medical Devices

Handling missing data is an important consideration in the analysis of data from all kinds of medical device studies. Missing data in medical device studies can arise for all the reasons one might expect in pharmaceutical clinical trials. In addition, they occur by design, in nonrandomized device studies, and in evaluations of diagnostic tests. For dichotomous endpoints, a tipping point analysis can be used to examine nonparametrically the sensitivity of conclusions to missing data. In general, sensitivity analysis is an important tool to study deviations from simple assumptions about missing data, such as the data being missing at random. Approaches to missing data in Bayesian trials are discussed, including sensitivity analysis. Many types of missing data that can occur with diagnostic test evaluations are surveyed. Careful planning and conduct are recommended to minimize missing data. Although difficult, the prespecification of all missing data analysis strategies is encouraged before any data are collected.

[1]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .

[2]  Bradley Efron,et al.  Missing Data, Imputation, and the Bootstrap , 1994 .

[3]  M. Pepe The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[4]  A Hadgu,et al.  Discrepant analysis: a biased and an unscientific method for estimating test sensitivity and specificity. , 1999, Journal of clinical epidemiology.

[5]  J. Schafer,et al.  Missing data: our view of the state of the art. , 2002, Psychological methods.

[6]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[7]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[8]  Huiman X Barnhart,et al.  A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present , 2003, Statistics in medicine.

[9]  P W Lavori,et al.  A multiple imputation strategy for clinical trials with truncation of patient data. , 1995, Statistics in medicine.

[10]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[11]  R A Greenes,et al.  Assessment of diagnostic tests when disease verification is subject to selection bias. , 1983, Biometrics.

[12]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[13]  Heng Li,et al.  Statistical and Regulatory Issues in Nonrandomized Medical Device Clinical Studies , 2008, Journal of biopharmaceutical statistics.

[14]  D M Hawkins,et al.  Some issues in resolution of diagnostic tests using an imperfect gold standard , 2001, Statistics in medicine.

[15]  Gregory Campbell Statistics in the World of Medical Devices: The Contrast with Pharmaceuticals , 2008, Journal of biopharmaceutical statistics.

[16]  P. Albert,et al.  A Cautionary Note on the Robustness of Latent Class Models for Estimating Diagnostic Error without a Gold Standard , 2004, Biometrics.

[17]  Lilly Q Yue,et al.  Statistical and Regulatory Issues with the Application of Propensity Score Analysis to Nonrandomized Medical Device Clinical Studies , 2007, Journal of biopharmaceutical statistics.

[18]  M. Kondratovich Comparing Two Medical Tests When Results of Reference Standard Are Unavailable for Those Negative via Both Tests , 2007, Journal of biopharmaceutical statistics.

[19]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[20]  Xu Yan,et al.  Missing Data Handling Methods in Medical Device Clinical Trials , 2009, Journal of biopharmaceutical statistics.

[21]  B Bunnag,et al.  Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. , 1987, American journal of epidemiology.

[22]  M. Tanner Tools for statistical inference: methods for the exploration of posterior distributions and likeliho , 1994 .